Peptide Antibiotics Market Report 2025

This Peptide Antibiotics report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The peptide antibiotics market size has grown rapidly in recent years. It will grow from $5.25 billion in 2024 to $5.82 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to discovery and development of peptide antibiotics, increased antibiotic resistance, rise inThe incidence of infectious diseases, advances in peptide synthesis technologies, growth ofThe pharmaceutical industry.

The peptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $8.47 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to emphasis on novel antibiotics development, increasing global incidence of antibiotic-resistant infections, expansion of research and development in antimicrobial peptides, regulatory support for new antibiotic approvals. Major trends in the forecast period include exploration of natural sources for antimicrobial peptides, application of peptide antibiotics in animal health, focus on peptide engineering for enhanced efficacy, development of combination peptide antibiotics, integration of ai and machine learning in peptide antibiotic discovery.

The rising prevalence of various infectious diseases is anticipated to drive the growth of the peptide antibiotics market. Infectious diseases are caused by harmful microorganisms, including bacteria, fungi, and parasites. Key factors contributing to the increase in infectious diseases include rapid urbanization, climate change, and a heightened risk of disease emergence, all of which have led to a greater demand for peptide antibiotics. Peptide antibiotics work by physically disrupting cell membranes, which underpins their antibacterial activity. For example, in May 2024, the World Health Organization, a Switzerland-based intergovernmental organization, reported that dengue cases in the Americas had already exceeded seven million by April 2024, significantly surpassing the 4.6 million cases recorded for the entire year of 2023. Therefore, the rising incidence of infectious diseases is fueling the growth of the peptide antibiotics market.

An increase in the prevalence of chronic diseases is expected to propel the growth of the peptide antibiotics market. Chronic diseases are defined as illnesses lasting a year or longer that require ongoing medical attention and restrict daily activities. The rise in chronic diseases can be attributed to factors such as increased tobacco use, poor nutrition, physical inactivity, and excessive alcohol consumption. Peptide antibiotics are utilized to treat chronic diseases by delivering the drug directly to the target area. For example, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected that by 2050, there would be over 35 million new cancer cases, reflecting a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of chronic conditions is driving the expansion of the peptide antibiotics market.

A prominent trend in the peptide antibiotics market is the increasing adoption of strategic partnerships among major companies. This collaborative approach allows companies to expand their market reach and leverage each other's resources effectively. For instance, Berkeley Lights, a US-based digital cell biology company, forged a strategic partnership with Aanika Biosciences in January 2022. Through this collaboration, Aanika Biosciences aims to utilize Berkeley Lights' high-throughput, functional screening service to rapidly identify and refine functional antimicrobial peptides (AMPs) targeting harmful bacteria, particularly those responsible for foodborne disease outbreaks. The partnership also involves the utilization of the Beacon Optofluidic Platform to identify peptides harmful to bacteria, leading to the development of a novel antibacterial tag. This tag will be integrated into Aanika Biosciences' bacterial spore-based barcoding technology to enhance food supply chain security.

Major players in the peptide antibiotics market are also making strategic moves by introducing generic versions, providing a cost-effective alternative for patients. Generic versions, which are off-patent alternatives to brand-name peptide-based antibiotics, offer affordability without compromising efficacy. In July 2023, Camber Pharmaceuticals, a US-based pharmaceutical company, expanded its portfolio by launching a generic version of Daptomycin for Injection. This peptide antibiotic is a cyclic lipopeptide synthesized by nonribosomal machinery and is prescribed for treating complicated skin and skin structure infections (cSSSI) in both adult and pediatric patients aged 1 to 17 years.

Major companies operating in the peptide antibiotics market include Eli Lilly and Company, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sandoz International GmbH, Xellia APS, Johnson & Johnson Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Lupin Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Ltd., Zydus Lifesciences Limited, Alkem Laboratories Limited, Allecra Therapeutics GmbH, Antabio, Basilea Pharmaceutica Ltd., BioVersys AG.

North America was the largest region in the peptide antibiotics market in 2024. The regions covered in the peptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the peptide antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The peptide antibiotics market consists of sales of oral, intravenous, intramuscular and topical peptide antibiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Peptide antibiotics are a type of antibiotics composed of peptides, and their antibacterial activity is based on the physical rupture of cell membranes. These antibiotics are designed to permeate bacterial membranes, accumulate within bacteria, and subsequently interfere with bacterial functioning.

The main types of peptide antibiotics include ribosomally synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. Ribosomally synthesized peptide antibiotics can either destroy or modify the drug, change the drug target, decrease or raise drug uptake, or substitute a different metabolic step as the medication's target. These antibiotics are antimicrobial peptides generated by ribosomes and produced by a wide range of species, from bacteria to plants and animals. Some examples of drugs under the category of peptide antibiotics include daptomycin, dalbavancin, telavancin, and other drugs used to treat various diseases such as skin infections, hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP), bloodstream infections, and other conditions. Peptide antibiotics are utilized and distributed through channels like hospitals, homecare, specialty clinics, and other distribution channels.

The peptide antibiotics market research report is one of a series of new reports that provides peptide antibiotics market statistics, including peptide antibiotics industry global market size, regional shares, competitors with a peptide antibiotics market share, detailed peptide antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide antibiotics industry. This peptide antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.